Subset analysis from the phase II/III trials, in small numbers of R/R FLT3-mutated AML patients who had prior exposure to sorafenib or midostaurin and were subsequently treated at R/R presentation with either quizartinib or gilteritinib, demonstrated lower, but still meaningful CRc rates of 25–30% [5, 10]. Here, FLT3 is linked to acute myeloid leukemia.